Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of KC1036 in advanced recurrent or metastatic thymic tumors
CTR20223423Phase 2Active
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of connitinib in thymoma and thymic carcinoma (TC), sponsored by Beijing Konruns Pharmaceutical Co., Ltd. Primary endpoint: Objective response rate. Started Feb 2023; status: active.
02
Drugs
connitinib
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on CTR20223423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223423.